No Data
No Data
Baixin International (00574.HK): Lou Zhenye Appointed as Independent Non-Executive Director
Gelonghui, May 20, 丨 Baixin International (00574.HK) announced that with effect from May 20, 2024, (i) Lou Zhenye has been appointed as an independent non-executive director and respective member of the Board Review Committee and Remuneration Committee; and (ii) Wang Dongyuan has been appointed as an independent non-executive director and a respective member of the Board Nomination Committee and the Corporate Governance Committee.
Pa Shun International In Talks With Hongtai Pharma for Chinese Medicine Collaboration
Pa Shun International Holdings (HKG:0574) signed a memorandum of understanding with Hongtai Pharmaceutical Technology to collaborate on Chinese medicine R&D, production, and distribution. Hongtai Phar
百信國際:年報 2023
Baixin International (00574.HK) appoints Yuan Hongbing as Chairman of the Board
Gelonghui, April 2, 丨 Baixin International (00574.HK) announced that with effect from April 2, 2024, (i) Mr. Yuan Hongbing, the current executive director, has been appointed as the chairman of the board of directors; (ii) Mr. Ma Qinghai has been appointed as the executive director and CEO of the company; (iii) Mr. Chen Zhongzheng has been appointed as a non-executive director; and (iv) Mr. Zhou Jinkai has been appointed as a non-executive director.
Baixin International (00574) appoints Ma Qinghai as Executive Director and Chief Executive Officer
Baixin International (00574) announced that since April 2, 2024, the current executive director Mr. Yuan Hongbing has been appointed...
Baixin International Announces 2023 Annual Results: Profit attributable to shareholders of 2.35 million yuan, turning a year-on-year loss into a profit
Baixin International (00574) announced annual results for the year ended December 31, 2023. The group obtained revenue of RMB 129 million (same unit), an increase of 80.3% over the previous year; profit attributable to the company's equity holders of RMB 2.35 million; a loss of RMB 43.379 million for the same period last year; and earnings per share of 0.16 points.
No Data